Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma

Table 4 An independent set of 44 GBM specimens to examine the effects of nuclear FABP7 and EGFR expression on patient survival

Case #	Diagnosis	Age	Survival (wk)	Censor	FABP7 Nu	EGFR IHC	New Category*
17	GBM	54.2	73.2	1	0	0	0
30	GBM	24.3	203.9	1	0	0	0
45	GBM	45.2	67.9	1	0	0	0
46	GBM	26.9	146.7	0	0	0	0
66	GBM	17.5	133.5	0	0	0	0
68	GBM	31.6	146.9	1	0	0	0
81	GBM	51.1	60.6	1	0	0	0
84	GBM	43.6	66.8	0	0	0	0
87	GBM	59.9	43.4	1	0	0	0
91	GBM	46.4	383.0	0	0	0	0
94	GBM	54.0	33.7	1	0	0	0
98	GBM	39.1	48.6	1	0	1	1
99	GBM	56.9	128.1	1	0	1	1
107	GBM	59.1	79.8	1	0	2	1
110	GBM	45.2	35.1	1	0	2	1
148	GBM	59.8	35.1	1	0	2	1
194	GBM	54.8	32.7	1	0	2	1
225	GBM	54.1	94.3	1	0	2	1
243	GBM	50.6	76.8	1	0	2	1
263	GBM	54.7	123.1	1	0	2	1
277	GBM	42.5	25.1	0	0	2	1
284	GBM	47.7	92.3	1	0	2	1
29	GBM	35.3	97.0	1	0	2	1
89	GBM	55.2	45.1	1	1	0	2
273	GBM	42.5	39.0	0	1	0	2
4	GBM	51.0	29.5	1	1	0	2
21	GBM	59.3	32.7	1	1	0	2
32	GBM	58.2	22.1	1	1	0	2
53	GBM	51.2	23.8	1	2	0	2
54	GBM	33.1	32.7	0	2	0	2
58	GBM	37.2	31.1	1	2	0	2
61	GBM	12.8	12.3	0	2	0	2
88	GBM	52.2	93.9	1	2	0	2
100	GBM	45.8	11.3	1	2	0	2
103	GBM	55.1	13.9	1	2	2	3
105	GBM	41.7	46.1	1	2	2	3
106	GBM	43.8	10.5	0	2	2	3
207	GBM	51.3	27.1	1	2	2	3
240	GBM	45.2	13.3	1	2	2	3
247	GBM	58.7	43.3	1	2	2	3
265	GBM	58.8	80.1	1	2	2	3
34	GBM	54.4	36.0	1	1	1	3
38	GBM	23.0	24.1	1	1	2	3
50	GBM	25.0	41.0	1	1	2	3

*Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual positive as "3"

ISSN: 1471-2407